Erlotinib ‘dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

@inproceedings{Mita2011ErlotinibA,
  title={Erlotinib ‘dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer},
  author={Alain C. Mita and Kyriakos P. Papadopoulos and Maja J. A. de Jonge and Gary Schwartz and Jaap Verweij and Monica M. Mita and Antoni Ricart and Quincy S-C Chu and Anthony William Tolcher and Laura C. Wood and Suzanne McCarthy and Mark D. Hamilton and Kasumi Iwata and Bret Wacker and Karsten Witt and Eric K. Rowinsky},
  booktitle={British Journal of Cancer},
  year={2011}
}
Background:To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that associated with a maximal level of tolerable skin toxicity (i.e., target rash (TR)); to characterise the pharmacokinetics (PK) and pharmacodynamics (PD) of higher doses of erlotinib.Methods:Patients initially received erlotinib 150 mg per day. The dose was successively increased in each patient to that associated with a TR… CONTINUE READING
9 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data

  • E Van Cutsem, Y Humblet, +7 authors M Peeters
  • 2007
Highly Influential
8 Excerpts

A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with chemotherapy

  • U Gatzemeier, J Baselga
  • Clin Cancer Res
  • 2008

Similar Papers

Loading similar papers…